Table 3.

Associations between clinical factors, and progression-free survival and overall survival for patients with low body surface area (<1.48 m²)

Factors	Univariate analysis PFS			Multivariate analysis PFS			Univariate analysis OS			Multivariate analysis OS
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Sex (male/female)	1.63	0.62–3.54	0.29	2.18	0.80–5.08	0.11	1.68	0.49–4.31	0.36	1.73	0.49–4.72	0.35
Age (<75/≥75 years)	1.76	1.05–2.93	0.03	2.03	1.12–3.67	0.01	0.74	0.39–1.33	0.32	0.79	0.39–1.55	0.50
PS (0–1/2–4)	0.42	0.24–0.79	<0.01	0.41	0.24–0.85	0.01	0.28	0.14–0.58	<0.01	0.26	0.12–0.56	<0.01
Clinical stage (III/IV + recurrence)	0.47	0.17–1.04	0.06	0.55	0.20–1.30	0.19	0.50	0.15–1.27	0.16	0.87	0.24–2.36	0.80
EGFR type (exon 19 del/exon 21 L858R)	0.83	0.50–1.38	0.49	0.71	0.39–1.26	0.25	0.36	0.19–0.66	<0.01	0.41	0.20–0.79	<0.01

BSA body surface area, HR hazard ratio, CI confidence interval, PS performance status, EGFR epidermal growth factor receptor, PFS progression-free survival, OS overall survival

Italic p values are statistically significant (p < 0.05)